Loading…
← CockpitCompetitor Analysis › 300357.SZ Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Class A300357.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang-based bio-pharmaceutical manufacturer selling drugs and health products in China.

Momentum strong 78
Mkt cap
$1.67B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$30.1M
20-day average traded
Fwd P/E
26.3×
forward earnings
ROIC−WACC
+8.9 pp
WACC 11.4%
Hurdle
+8 pp
Req g minus delivered
Next earnings
149 days
16 Apr 2027
Close · CNYCN¥21.24
1D-1.6%
1W-3.1%
1M+10.3%
3M-17.7%
6M-11.9%
YTD-25.1%
1Y-37.6%
ATR %3.2%
52w lowhigh37.2% off high

What Zhejiang Wolwo Bio-Pharmaceutical does

Zhejiang-based bio-pharmaceutical manufacturer selling drugs and health products in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics/biopharma

Moat: none

Headquarters: Zhejiang, China · Employees: 1,808

Zhejiang Wolwo Bio-Pharmaceutical at a glance

Size Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.67B, the 1369th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.24 on 18 Nov 2026.

Performance Over six months the shares fell 11.9%, against -3.0% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 6.8% over the last twelve months (peer median +13.8%); the operating margin is 38.8% (peer median 12.0%).

Valuation It trades at 26.3× forward earnings against a peer median of 22.0× (8th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.9 points above its cost of capital (11.4% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 96300357.SZ 90
Six months, rebased to 100: Zhejiang Wolwo Bio-Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Wolwo Bio-Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.12BCN¥1.06BCN¥922MCN¥845MCN¥893M
Revenue growth—+15%+9%-5%—
Gross profitCN¥1.07BCN¥960MCN¥834MCN¥772MCN¥827M
EBITDAn/aCN¥456MCN¥368MCN¥345MCN¥367M
Net incomeCN¥427MCN¥381MCN¥318MCN¥310MCN¥349M
Free cash flowCN¥448MCN¥307MCN¥147MCN¥179MCN¥180M
Capital expenditureCN¥41.4MCN¥119MCN¥118MCN¥209MCN¥189M
Total debtCN¥12.1MCN¥18.4MCN¥25.6MCN¥62.4MCN¥16.3M

Quarterly statements and history in the cockpit →

Zhejiang Wolwo Bio-Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-20%0%+20%INDGN6009931681CAPLIPOINT300723FAEMAZE688166NATCOPHARM000766ASTRAZENANURAS301047002755600420JUBLPHARMAAGIO300357.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Wolwo Bio-Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×80×INDGN6009931681CAPLIPOINT300723FAE688166NATCOPHARMANURAS301047002755600420JUBLPHARMA0026759989300357.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Wolwo Bio-Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%INDGN6009931681CAPLIPOINT300723FAE688166NATCOPHARM000766ASTRAZEN3010470027556004200026759989300357.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Wolwo Bio-Pharmaceutical is the large dot.

Zhejiang Wolwo Bio-Pharmaceutical competitors and peer comparison

How Zhejiang Wolwo Bio-Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Wolwo Bio-Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300357.SZPeer medianRank in peer set
1-month return+10.3%-3.2%3rd highest of 21
6-month return-11.9%-3.0%9th lowest of 20
Distance from 52-week high-37.2%-32.1%8th lowest of 21
Revenue growth (TTM)+6.8%+13.8%10th lowest of 20
Operating margin38.8%12.0%highest of 20
Forward P/E26.3×22.0×8th most expensive of 16
Growth the price implies (Req g, 7 yrs)18.4%12.8%8th most demanding of 16
Growth delivered (Del g)+10.8%+6.8%6th highest of 16
Hurdle (Req g minus delivered)+7.6 pp+8.6 pp8th least demanding of 16
ROIC minus cost of capital+8.9 pp-2.7 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%29.0×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%47.2×6.0%-4.3%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%

Questions

Which companies are Zhejiang Wolwo Bio-Pharmaceutical's closest peers?
The cockpit's peer set: Braveheart Bio (BRVE), Indegene (INDGN.NS), Mayinglong Pharmaceutical (600993.SS), Consun Pharmaceutical (1681.HK), Caplin Point Laboratories (CAPLIPOINT.NS), ApicHope Pharmaceutical (300723.SZ), Faes Farma (FAE.MC), Maze Therapeutics (MAZE).
Is Zhejiang Wolwo Bio-Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 26.3× against a peer median of 22.0×, 8th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zhejiang Wolwo Bio-Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -11.9% against -3.0% for the median peer; over one year -37.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.